bestpokerbooks| Fosun Pharma (02196.HK): Supplementary application for new indications for adalimumab injection approved

Glonghui May 22 丨 Fosun Pharma (600196)(02196bestpokerbooks.HK) Announcementbestpokerbooks, independently developed by Shanghai Fuhong Hanlius Biotechnology Co., Ltd., a controlling subsidiary of Shanghai Fosun Pharma (Group) Co., Ltd.(hereinafter referred to as the "Company"), and its controlling subsidiary (hereinafter collectively referred to as "Fuhong Hanlius"). Yuan (i.e., adalimumab injectionbestpokerbooks, hereinafter referred to as "the drug") A supplementary application for four new indications (1) polyarticular juvenile idiopathic arthritis,(2) childhood plaque psoriasis,(3) Crohn's disease, and (4) childhood Crohn's disease (hereinafter collectively referred to as the "new indications") was recently approved by the State Food and Drug Administration.

This drug is an adalimumab biosimilar independently developed by the group (i.e. the company and its holding subsidiaries/units, the same below). As of the date of this announcement, the approved indications for this drug include (1) rheumatoid arthritis,(2) ankylosing spondylitis,(3) psoriasis,(4) uveitis,(5) polyarticular juvenile idiopathic arthritis,(6) pediatric plaque psoriasis,(7) Crohn's disease, and (8) pediatric Crohn's disease. As of April 2024, the Group's cumulative R & D investment in this drug at this stage is approximately RMB28.bestpokerbooks, 8.66 million yuan (unaudited).